About Wolverine.

What Wolverine is.

Wolverine is a US peptide subscription brand and editorial publication launching in the post-RFK regulatory window. We write science journalism on peptide therapy and operate a forthcoming subscription clinical platform.

The brand exists at the intersection of evidence-based performance and the regulatory shift underway in 2026. Our editorial mission: become the most-cited independent voice on peptide therapy before FDA reclassification arrives — then convert that authority into a qualified patient waitlist on day one of clinical launch.

Who Wolverine is for.

Performance-minded biohackers and longevity-focused adults aged 28–55. The Wolverine reader follows Andrew Huberman, Peter Attia, and Joe Rogan. They track sleep with a Whoop. They take Momentous supplements. They are already evaluating or using grey-market peptide compounds and they want a science-journalism source that takes the topic seriously — without crossing into clinical recommendation.

They do not want soft, empathetic, "we are here to listen" healthcare-brand language. They want mechanism-of-action explainers, regulatory analysis, third-party testing data, and an opinionated editorial perspective.

What Wolverine is not.

• Not a clinic in Phase 2. The regulated clinical platform — prescribing, telehealth onboarding, compounding pharmacy integration — launches at app.wolverine.health after FDA reclassification. That surface has its own compliance posture, its own HIPAA-compliant infrastructure, and its own clinical advisory structure.
• Not selling peptides on this site. Wolverine does not sell, dispense, or facilitate access to peptide compounds. We write about them.
• Not making clinical recommendations. Nothing on wolverine.health constitutes medical advice, diagnosis, treatment, or prescribing. Consult a licensed clinician before making any decision about your health. The science-journalism lane is enforced until a named clinical advisor is in place.

How Wolverine is built.

The publication runs on a four-stage AI-assisted content pipeline: signal ingestion from regulatory, scientific, and audience sources; a structured research corpus; a dialectic editorial step that surfaces tensions in evidence and industry positioning; and a publish layer optimised for both AI citation and traditional search. Every article passes a human editorial review before it is published.

The content factory and the forthcoming clinical platform share infrastructure but are deliberately separated by compliance posture. Decisions made today — vendor selection, data handling, BAA-readiness — are designed not to block HIPAA-compliant operations in the next milestone.

See Editorial Methodology for how articles are researched, drafted, and reviewed. See Editorial Standards for sourcing, attribution, and corrections policy.